Summary
Oliver Howes is Group Head and Professor of Molecular Psychiatry. His clinical work is as Consultant Psychiatrist at The Institute of Psychiatry/ Maudsley Hospital.
Contact: tel: +44 (0)20 8383 3298
Mental illnesses are a major cause of ill health and premature death. They account for four of the six leading causes of adult disability in the world and one in every ten hospital beds in the UK is allocated for the treatment of psychotic disorders such as schizophrenia.
“Our research focuses on understanding the causes of mental illnesses and improving their treatment using PET and other functional imaging techniques"
Current work in the group focuses on:
- Understanding the brain changes that lead to the development of psychotic disorders, using multi-modal imaging with PET and MRI
- Examining the effects of cannabis and other drugs on the brain, and the influence of common genetic polymorphisms on brain function
- Determining why some patients respond to treatments and others don’t
- Using novel approaches to diagnosing mental illnesses
- Developing models for future drug development
Publications
Journals
Howes OD, Baxter L, 2023, The drug treatment deadlock in psychiatry and the route forward, World Psychiatry, Vol:22, ISSN:1723-8617, Pages:2-3
Pillinger T, Osimo EF, de Marvao A, et al. , 2023, Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study, The Lancet Psychiatry, Vol:10, ISSN:2215-0366, Pages:98-107
Egerton A, Griffiths K, Casetta C, et al. , 2023, Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration., Neuropsychopharmacology, Vol:48, Pages:567-575
Sathyanarayanan A, Mueller TT, Ali Moni M, et al. , 2023, Multi-omics data integration methods and their applications in psychiatric disorders., Eur Neuropsychopharmacol, Vol:69, Pages:26-46
Kaar SJ, Nottage JF, Angelescu I, et al. , 2023, Gamma Oscillations and Potassium Channel Modulation in Schizophrenia: Targeting GABAergic Dysfunction., Clin Eeg Neurosci